Market Trends of ELISA Analyzer Industry
Automated ELISA Analyzers are Expected to Witness High Growth During the Forecast Period
The increasing burden of infectious diseases globally has fueled the demand for advanced ELIZA systems, including automated immunoassay platforms, fueling segment expansion.
Automated ELISA analyzers have various advantages over semi-automated ELISA analyzers. Thus, this makes them a preferred choice in testing laboratories. For instance, automation provides the possibility of a walk-away workflow that saves time. Also, other benefits of automated ELISA analyzers include increased accuracy in results, cost efficiency, and fast turnaround times.
According to May 2023 data from Berthold Technologies GmbH & Co.KG, automated ELIZA analyzers increase detection efficiency and help boost overall operation. Moreover, as per the same source, automation in ELISA systems can turn an ELISA's manual and tedious process into an easy, fast, and technician-free activity. Thus, several benefits associated with them are anticipated to bolster their adoption during the forecast period.
In addition, automation provides an increase in flexibility. For instance, with the help of software and robotic components, automated analyzers can turn into a flexible workstation that can easily adapt to the required application. Hence, these benefits lead to a surge in their demand, thereby driving the growth of the segment.
In addition, key companies operating in the market are adopting strategies to provide advanced automated ELISA analyzers. This, in turn, leads to a surge in demand for automated analyzers, thereby driving the growth of the segment. For instance, in May 2022, Molecular Devices LLC launched fully automated work cells for ELISA workflows that automate and streamline the ELISA detection, allowing a rapid and robust analysis of large-volume samples.
Thus, the above-mentioned factors, like the increasing burden of infectious diseases, rising preference for automated ELIZA analyzers owing to several associated benefits, and several strategic initiatives undertaken by market players, are projected to augment segment expansion during the forecast period.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
North America is expected to dominate the market. This is due to the surge in the prevalence of infectious diseases such as HIV, Lyme disease, hepatitis C, and other diseases that require ELISA testing. For instance, FAIR Health released a study in August 2022. The study claimed a substantial rise in Lyme disease diagnoses throughout the last decade in the United States rural and urban areas. Also, the results of the study indicated that private insurance claims associated with Lyme disease diagnoses increased by 357% in rural areas and 65% in urban areas.
Similarly, the alarming increase in infectious diseases like tuberculosis, malaria, respiratory infections, and other diseases has bolstered the demand for advanced immunoassay solutions. For instance, according to the CDC’s updated data for November 2023, tuberculosis is a disease with a significant burden in the United States that affected around 8,331 people in the country in 2022. In addition, an estimated 13 million people are living with latent TB infection in the United States. Thus, the surge in prevalence of infectious diseases in the region leads to a surge in demand for ELISA analyzers thereby driving the growth of the market.
Moreover, the rising adoption of ELISA-based systems in point-of-care settings is further projected to propel market growth forward. For instance, according to the Journal of HHS Public Access published in February 2022, ELISA systems have emerged as a potential POC diagnostic tool owing to the development of automated plate reader systems and easy operations. Moreover, technological advancements in immunoassay platforms and cost efficiency have made it a convenient tool for POC applications. Thus, the higher adoption of ELIZA systems in POC settings is projected to spur regional market growth.
Also, factors such as the presence of key players in the region lead to the easy availability of advanced automated ELISA analyzers, contributing to the market's growth. Some of the key players operating in the region include PerkinElmer Inc. (EUROIMMUN Medizinische Labordiagnostika AG), Eurofins Scientific (Eurofins Abraxis), Gold Standard Diagnostics Inc. (NovaTec Immundiagnostica GmbH), and Awareness Technology Inc. Therefore, the increasing burden of infectious disease, technological advancements in ELIZA platforms, and increasing adoption of ELIZA systems at POC are projected to support the market growth over the coming years.
